Boston Strategics Corporation Announces Licensing Deal with Eisai Co., Ltd.
BOSTON -- June 30, 2014
Boston Strategics Corporation (BSC), an integrated clinical-stage drug
research and development (R&D) company, Boston, MA, today announced that it
has entered into an exclusive licensing and development agreement with
Japanese global pharmaceutical company Eisai Co., Ltd., for Eisai's oncology
E6201 is a dual-targeted FLT3 and MEK inhibitor which has completed a Phase1
clinical trial showing preliminary antitumor activity and an acceptable safety
profile. Building on a strong scientific rationale supported by recent
preclinical data, BSC will undertake a clinical Proof of Concept (PoC) trial
in the high unmet need FLT3 mutated AML patients.
Under this agreement with Eisai, BSC has worldwide rights to develop and
commercialize E6201 for all Oncology indications.
This collaboration is a prime example of BSC applying its “True” Open
Innovation™ platform to develop drug candidates with potential to
significantly improve patients’ health care. As such it represents the next
step toward BSC’s vision to create a novel and comprehensive approach to
global pharmaceutical development.
“This is a critical milestone for BSC to validate our concept to move drug
development programs forward by increasing the Probability of Success (PoS)
and sharing risks with key strategic partners,” says Eita Kitayama, President
of Boston Strategics. “Eisai recognized the value of this approach and
entrusted BSC with the development of E6201 for cancer indications to build on
the foundation of this new platform. At BSC, we are deeply committed to
proving that our innovative approaches can deliver breakthrough therapies with
industry benchmark-beating timelines, quality, and financial investments, thus
limiting the ever increasing costs of pharmaceutical innovation and
About Boston Strategics Corporation (BSC)
BSC is an integrated drug R&D company with experience in developing, managing
and optimizing global drug development programs from late discovery, through
translational research, first-in-man and proof-of-concept studies.Its mission
is to continuously improve patient health care by changing the drug R&D
paradigm using “True” Open Innovation™ platform.
Boston Strategics Corporation
Luca Rastelli, 781-561-6553
Press spacebar to pause and continue. Press esc to stop.